Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine + MET/MBRP for Cannabis Use Disorder
NCT02946489Phase 1Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Oct 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind, single-arm trial of ketamine in cannabis use disorder (CUD), sponsored by New York State Psychiatric Institute. Primary endpoint: Percentage of Participants With Cannabis Abstinence or Significant Reduction in Cannabis Use at Week 6. Started Oct 2016; status: completed.
02
Drugs
ketamine
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT02946489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02946489.